Evidence map›Paper›PMID 35173420›Full record

ArticlePatient preference and adherence2022

Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of Oncology.

Mario Caccese, Silvia Imbevaro, Alessandra Feltrin, Daniela Costardi, Nadia Giordano, Maristella Maran, Rosalba Martino, Ketti Ottolitri, Malihe Shams, Federica Vascon and 8 more

Abstract read
In one paragraph

Article in Patient preference and adherence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mario CacceseDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.ORCID 0000-0002-0059-5660
Silvia ImbevaroGeneral Directorate, Accreditation and Acknowledgment Unit, Veneto Institute of Oncolog IOV - IRCCS, Padua, Italy.
Alessandra FeltrinHealth Department, Psycho-Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Daniela CostardiScientific Directorate, Patient Education and Empowerment, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Nadia GiordanoDepartment of Oncology, Oncology 3, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Maristella MaranDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Rosalba MartinoDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Ketti OttolitriHealth Department, Clinical Risk Office, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Malihe ShamsHealth Department, Psycho-Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Federica VasconDepartment of Imaging and Health Physics, Radiotherapy Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Anna RomaDepartment of Oncology, Oncology 3, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Antonella GalianoDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Marco MaruzzoDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Dario MarinoDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Giuseppe LombardiDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Sara LonardiDepartment of Oncology, Oncology 3, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.ORCID 0000-0002-7593-8138
Antonella BrunelloDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Vittorina ZagonelDepartment of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe SARS-CoV-2 spread has impacted Healthcare systems. COVID-19 pandemic has had consequences for patients with cancer, being associated with delays in diagnosis, in treatment And follow-up care, increase in overall infection rates and higher mortality. A survey on COVID-19 and a vaccination-questionnaire were developed at different times of the outbreak, to evaluate cancer patient-reported experience measures (PREMs) on the policies implemented to reduce the infection from SARS-CoV-2 and on the timing and methods of COVID-19 vaccination. PATIENTS AND

methodsThe survey was distributed to all patients accessing the Institute during the "first-wave" Of the pandemic, evaluating patients' concerns about the pandemic, the pandemics' consequences on their cancer care, and their perception Of the measures adopted to limit the infection spread. The vaccination-questionnaire was proposed to 10% of the first 5297 cancer patients vaccinated with two doses of the Pfizer-BioNTechCOVID-19 vaccine. This questionnaire aimed at assessing the degree Of satisfaction with the Institutional vaccination campaign and vaccination-related adverse events.

resultsFrom May 18th 2020 to June 15th 2020 the survey was completed by 3238 patients. Most of the responders expressed concern on the pandemic yet acknowledging their oncological disease as a priority. Measures implemented were appreciated by patients. Telemedicine was positively evaluated and the absence of the caregiver during the visit did not determine discomfort for two thirds of patients. From March 6th 2021 to May 8th 2021 the vaccination-questionnaire was completed by 357 patients. The 98.8% were satisfied with the vaccination campaign. No serious vaccination-correlated adverse events were reported. No patient had to delay/discontinue chemotherapy due to vaccination.

conclusionPREMs during COVID-19 pandemic and related vaccination can provide important information to help reorganization of the health care systems for cancer care. Patients' feedback on the organizational changes implemented in the emergency period are essential for healthcare improvement and to help informed choices that are consistent with patients' needs.

Indexed as

cancer patientsCOVID-19patients’ perspectivePREMsSARS-CoV-2survey

Identifiers

PMID35173420
PMCPMC8841696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.